IMPORTANCE: Chronic pain is a leading cause of disability, and many affected patients rely on long-term opioid therapy despite its unfavorable adverse effect profile. Spinal cord stimulation is an established therapy for chronic pain that may secondarily reduce opioid consumption by providing sustained analgesia.
OBJECTIVE: To quantify changes in opioid use following spinal cord stimulation implantation for the treatment of chronic pain through a systematic review and meta-analysis.
DATA SOURCES: We conducted a comprehensive search of MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, and Scopus from each database's inception to July 1, 2024.
STUDY SELECTION: We included studies describing patients who underwent spinal cord stimulator implantation for the treatment of chronic pain. A total of 2,784 potential studies were identified and screened by multiple independent reviewers, yielding a final total of 43 studies included in the systematic review.
DATA EXTRACTION AND SYNTHESIS: Data extraction was completed by multiple independent reviewers following Preferred Reporting Items for Systematic Reviews and Meta-Analysis and Meta-analysis Of Observational Studies in Epidemiology guidelines. A random effects model with Hartung-Knapp-Sidik-Jonkman adjustment was used to estimate pooled estimates. Certainty assessment was performed following the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) framework.
MAIN OUTCOMES AND MEASURES: The primary outcomes were change in continuous opioid use (ie, morphine milligram equivalent (MME)) and categorical opioid use (yes/no) from preimplantation to 12 months following spinal cord stimulator implantation.
RESULTS: Meta-analysis of 12 month continuous MME use comprising 22 study comparisons (1,666 individuals) revealed a weighted mean difference of -18.06 MME (95% CI -24.41 to -11.70; 95% prediction interval -38.29 to 2.17; p<0.001). Meta-analysis of categorical opioid use at 12 months comprising 24 study comparisons (1,527 individuals) revealed an OR of 0.47 (95% CI 0.30 to 0.75; 95% prediction interval 0.10 to 2.11; p=0.003), signifying lower odds of opioid continuation.
CONCLUSIONS AND RELEVANCE: Spinal cord stimulation is associated with reduced opioid dose consumption and increased odds of opioid cessation at 12 months postimplantation compared with baseline in patients with chronic pain; however, both of these conclusions are supported by evidence of very low GRADE certainty.
PROSPERO REGISTRATION NUMBER: CRD42024574921.
| Discipline Area | Score |
|---|---|
| Physician |  |
Physician rater
Results that are entirely predictable and well-known. A study of no clinical interest. They analyze studies that are heavily biased by industry.
Physician rater
This meta-analysis is useful for managing chronic pain. It reviews spinal cord stimulation implantation for chronic pain through a systematic review and meta-analysis.
, McMaster University